Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab
Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...
Marketing Dive17d
Brand Strategy
The L’Oréal skincare brand is returning to its influencer-heavy Super Bowl marketing playbook from last year to boost a new anti-dandruff product.
Cure Today17d
Linvoseltamab BLA Resubmission Accepted by FDA for Review
Linvoseltamab's BLA resubmission is under FDA review, with a decision anticipated by July 2025, supported by LINKER-MM1 trial data. The trial evaluates linvoseltamab's safety, tolerability, and ...
MM&M17d
Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more
AbbVie got FDA approval for antibiotic treatment Emblaveo. Regeneron’s Linvoseltamab BLA was accepted for FDA review for the treatment of relapsed/refractory multiple myeloma. FDA has approved an ...
inkbotdesign.com18d
6 Spiritual Signs and Meanings in Famous Brand Logos
Discover the hidden meanings behind the logos! Uncover 6 spiritual signs that reveal deeper connections and insights in iconic logos designs. Every creator adds special meaning to their product. This ...
inkbotdesign.com18d
Top 20 Fashion Logos: Best Designs in the Industry
From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are the heartbeat of a brand's identity. They encapsulate what a brand stands ...
PipelineReview.com19d
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
TARRYTOWN, NY, USA I February 11, 2025 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the ...
Monthly Prescribing Reference20d
Linvoseltamab Under Review for Relapsed/Refractory Multiple Myeloma
Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...
Nasdaq20d
Regeneron Pharma Says FDA Accepted BLA For Linvoseltamab To Treat Multiple Myeloma
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Tuesday said that the resubmission of Biologics License Application (BLA) for linvoseltamab for the treatment of multiple myeloma has been ...
Finanznachrichten20d
Regeneron Pharmaceuticals, Inc.: Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
The BLA is supported by data from the pivotal LINKER-MM1 trial investigating linvoseltamab in R/R MM, and linvoseltamab is also under review by the European Medicines Agency (EMA) for the same ...